Multiple Endocrine Neoplasia Syndromes

MEN Syndromes Overview - Endocrine Ensemble

• Group of inherited disorders causing tumors in multiple (≥2) endocrine glands.
• Inheritance: Predominantly Autosomal Dominant (AD).
• Genetic cause: Germline mutations in specific genes (tumor suppressor or proto-oncogenes).
• Key feature: High predisposition to develop multiple primary endocrine tumors.
• Tumors often occur at a younger age than sporadic counterparts.

⭐ MEN syndromes are classic examples of inherited cancer predisposition due to germline mutations affecting tumor suppressor genes or proto-oncogenes (e.g., MEN1, RET).

MEN Type 1 (Wermer Syndrome) - Parathyroid's Pancreatic Pituitary Party

• Gene: MEN1 (menin) on chromosome 11q13. Autosomal Dominant.
• 📌 Mnemonic: "3 Ps"
  • Parathyroid (>90%): Hyperplasia/adenomas → Primary hyperparathyroidism (↑PTH, ↑$Ca^{2+}$). Most common.
  • Pancreatic Neuroendocrine Tumors (NETs) (~30-80%): Gastrinoma (Zollinger-Ellison syndrome - most common functional), insulinoma, VIPoma.
  • Pituitary adenoma (~15-50%): Prolactinoma (most common), GH-secreting, ACTH-secreting.
• Others: Carcinoid tumors (thymic, bronchial), adrenal cortical tumors, facial angiofibromas, collagenomas, lipomas.

⭐ Gastrinomas in MEN1 are frequently multiple and may occur in the duodenum (extrapancreatic).

MEN Type 2A (Sipple Syndrome) - Thyroid's Adrenal Parathyroid Trio

• Gene: RET proto-oncogene mutation (Chr 10q11.2).
• Inheritance: Autosomal Dominant.
• Classic Triad (📌 "MPT"):
  • Medullary Thyroid Carcinoma (MTC):
    • ~100% penetrance; often first sign.
    • Bilateral, multifocal; ↑ Calcitonin.
    • Prophylactic thyroidectomy advised.
  • Pheochromocytoma:
    • ~50%; often bilateral.
    • Episodic hypertension, palpitations.
    • Screen: plasma/urine metanephrines.
  • Primary Hyperparathyroidism:
    • ~20-30%; parathyroid hyperplasia.
    • ↑ PTH, ↑ $Ca^{2+}$.
• Screening: RET genetic testing for family members.

⭐ Medullary thyroid carcinoma (MTC) is the earliest and most frequent component. Prophylactic thyroidectomy is recommended for RET mutation carriers.

MEN Type 2B - RET's Rogue Roundup

• Gene & Inheritance:
  • RET proto-oncogene (codon 918 Met→Thr in >95%).
  • Autosomal Dominant (AD); ~50% de novo.
  • More aggressive phenotype vs. MEN2A.
• Key Clinical Manifestations (NO Hyperparathyroidism):
  • Medullary Thyroid Carcinoma (MTC): 100%, aggressive, early onset (infancy). Prophylactic thyroidectomy by age 1.
  • Pheochromocytoma: ~50%, often bilateral.
  • Mucosal Neuromas: Pathognomonic (lips, tongue, eyelids, GI).
• Associated Features:
  • Marfanoid habitus (tall, slim, arachnodactyly).
  • Intestinal ganglioneuromatosis (constipation, megacolon).
  • Thickened corneal nerves.
• 📌 Mnemonic: "2B": Bumps (neuromas), Big (Marfanoid), Bad MTC, Bilateral Pheos (often).

⭐ >95% of MEN2B cases stem from the RET Met918Thr mutation, causing aggressive MTC and unique features like mucosal neuromas, distinguishing it from MEN2A.

Diagnosis & Screening - Catching the Culprits

• Genetic Testing: Confirms diagnosis (MEN1, RET, CDKN1B genes). Essential for family screening.
• Biochemical Screening (Periodic):
  • MEN1: Serum Ca, PTH, gastrin, prolactin.
  • MEN2A/2B: Plasma calcitonin, metanephrines; Serum Ca/PTH (MEN2A).
• Imaging (CT, MRI): Localizes tumors after biochemical flags.

⭐ Early calcitonin screening in RET mutation carriers is vital. Prophylactic thyroidectomy by age 5 (MEN2B) or early childhood (high-risk MEN2A).

High‑Yield Points - ⚡ Biggest Takeaways

• MEN 1 (Wermer's): 3Ps - Parathyroid, Pancreatic (gastrinoma, insulinoma), Pituitary. MEN1 gene.
• MEN 2A (Sipple's): Medullary Thyroid Carcinoma (MTC), Pheochromocytoma, Parathyroid hyperplasia. RET gene.
• MEN 2B: MTC (aggressive), Pheochromocytoma, Mucosal neuromas/Marfanoid habitus. NO Parathyroid. RET gene.
• MTC is universal in MEN 2A/2B; prophylactic thyroidectomy is crucial.
• Pheochromocytoma in MEN 2 syndromes is often bilateral.
• All MEN syndromes: Autosomal Dominant inheritance; screen family.
• Key genes: MEN 1 → MEN1 gene; MEN 2A/2B → RET proto-oncogene.